Anaxomics, member of CataloniaBio & HealtTech, announced the appointment of Peter M. Windisch as its Chief Executive Officer (CEO), effective September 1st, 2023. 

Mr. Windisch brings with him a wealth of experience, boasting an illustrious 30-year career in senior and executive leadership positions within the CRO Industry. His most recent roles include serving as Chief Technology Officer at Excelya in France, and previously as Vice President Operations and General Partner at PRA, and Vice President Operations Western Europe at RPS (now ICON). With his profound expertise, Anaxomics is well-positioned to enhance its service offerings in in-silico studies and expand its clientele both locally and internationally. 

As part of a strategic leadership transition, Jose Manuel Mas, the outgoing CEO, will assume the role of Chief Scientific Officer (CSO). In this capacity, he will lead the charge in developing innovative AI-based tools to keep Anaxomics at the cutting edge of the competitive market. 

"We are thrilled to welcome Peter M. Windisch as our new CEO. His extensive experience and proven leadership will undoubtedly drive Anaxomics towards new horizons, enabling us to better serve our clients and expand our reach across diverse regions," said Jose Manuel Mas, the new Chief Scientific Officer. 

Anaxomics is a leading AI Biotech Company based in Barcelona specializing in Systems Biology technologies and In Silico Clinical Trials. The company is dedicated to using advanced AI tools to overcome challenges in drug discovery and development, ultimately contributing to the advancement of global healthcare.